Lipoxen Announces $75M Agreement with Baxter to Develop New Blood Clotting Factors
Lipoxen PLC announced that the company has entered into an exclusive worldwide development and licence agreement with a subsidiary of Baxter International Inc. to develop improved, longer-acting forms of blood-clotting factors. The signing of this agreement by Baxter triggers a $1 million payment to Lipoxen, and the agreement includes further clinical and regulatory milestone payments to Lipoxen potentially worth up to a total of $75 million, plus royalties on future product sales.
Lipoxen's PolyXen(r) protein drug delivery technology links therapeutic proteins, or peptides, to the naturally occurring polymer polysialic acid to prolong protein stability and biological half-life, and to improve solubility and immunological characteristics while maintaining biological activity and minimizing toxicity. Conjugating PolyXen(r) to therapeutic blood-clotting factors aims to improve pharmacokinetic profile and extend active life in order to reduce the frequency of injections required to treat blood-clotting disorders such as haemophilia A.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Biotest recorded revenues of EUR 218 million in 2004
NascaCell announces an aptamer distribution agreement in Japan with GE Healthcare
XOMA Announces Planned Retirement of Chief Executive Officer
East German physicians prescribe significantly more high-priced biopharmaceutical medication than West German doctors - 127% higher revenues of pharmaceutical companies per physician and year in the area of former East Germany
Apeiron announces start of phase I trail with cellular anti cancer therapy
Tecan and the Monash Antibody Technologies Facility unveil custom monoclonal antibody production facility
Acacia Pharma starts clinical trial with APD515 for Xerostomia
